SYRS(Delisted)
Syros·NASDAQ
--
--(--)
SYRS Profile
Syros Pharmaceuticals, Inc.
A company that developing gene control medicines for the treatment of cancer and immune-mediated diseases
35 CambridgePark Drive, 4th Floor, Cambridge, Massachusetts 02140
--
Syros Pharmaceuticals, Inc., was incorporated under the laws of the State of Delaware on November 9, 2011. The company is a biopharmaceutical company dedicated to developing new standards of care for first-line treatment of patients with hematological malignancies. The company is advancing a late-stage clinical program that includes lead product candidates: (i) Tamibarotene, a selective retinoic acid receptor α agonist, and the company is conducting SELECT-MDS-1, a Phase 3 clinical trial evaluating Tamiflu in combination with azacitidine in patients with high-risk myelodysplastic syndromes (HR-MDS). (ii) SY-2101, a new oral form of arsenic trioxide or ATO, which was evaluated in a dose-confirmation study in newly diagnosed patients with low-risk acute promyelocytic leukemia or APL.
